Last reviewed · How we verify
MenitorixTM
Meningococcal conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y.
Meningococcal conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults.
At a glance
| Generic name | MenitorixTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal conjugate vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Meningitidis (Menitorix) is a tetravalent meningococcal conjugate vaccine combining polysaccharide capsules from serogroups A, C, W, and Y conjugated to a protein carrier. This conjugation enhances T-cell dependent immune responses, promoting both antibody production and immunological memory against these major disease-causing meningococcal strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |